GATE 101
Alternative Names: GATE-101Latest Information Update: 28 Nov 2023
At a glance
- Originator Gate Neurosciences
- Class Antidepressants; Sleep disorder therapies
- Mechanism of Action Metabotropic glutamate receptor 2 antagonists; Metabotropic glutamate receptor 3 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hypersomnia; Major depressive disorder
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for phase-I development in Hypersomnia(In volunteers) in USA (IV)
- 28 Nov 2023 No recent reports of development identified for phase-I development in Major depressive disorder(In volunteers) in USA (IV)
- 03 Aug 2022 Gate Neurosciences terminates a phase I trial in Hypersomnia (In volunteers) in USA (IV) due to reached biomarker endpoint (NCT04618263)